Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02499770
Title G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors G1 Therapeutics, Inc.
Indications

lung small cell carcinoma

Therapies

Carboplatin + Etoposide

Trilaciclib

Age Groups: adult
Covered Countries USA | FRA | ESP


No variant requirements are available.